TRIPTOCAL NAP

This brand name is authorized in Ecuador

Active ingredients

The drug TRIPTOCAL NAP contains a combination of these active pharmaceutical ingredients (APIs):

1 Sumatriptan
UNII J8BDZ68989 - SUMATRIPTAN SUCCINATE

Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D) receptor agonist with no effect on other 5HT receptor (5-HT2 - 5-HT7) subtypes. The vascular 5-HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction.

Read about Sumatriptan
2 Naproxen
UNII 9TN87S3A3C - NAPROXEN SODIUM

Naproxen is a non-steroidal anti-inflammatory analgesic compound with antipyretic properties as has been demonstrated in classical animal test systems. Naproxen exhibits its anti-inflammatory effect even in adrenalectomised animals, indicating that its action is not mediated through the pituitary-adrenal axis.

Read about Naproxen

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 5157-MEE-0520

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈